Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
metastatic colorectal cancer treatment
market8 mentionslast seen Nov 10, 2026
Market for advanced treatment of colorectal cancer with liver metastases.
Relationships 3
Relationship
PDS0301applies tometastatic colorectal cancer treatment
99% confidence5 supporting mentions
Either name opens that entity’s relationships.
Sources 5
- filingSEC EDGARNov 10, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
advancement of PDS0301 toward a Phase 3 trial in metastatic colorectal cancer
- filingSEC EDGAROct 20, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS0301 (Tumor-Targeted IL-12 Immunocytokine) in an NCI-led Phase 2 trial in MSS/pMMR metastatic colorectal cancer (mCRC) with liver metastases
- filingSEC EDGAROct 20, 2026PDS Biotechnology Corp 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Phase 3 trial in Metastatic Colorectal Cancer (mCRC)
- filingSEC EDGARSep 22, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC)
- filingSEC EDGARSep 21, 2026PDS Biotechnology Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PDS0301 + Chemotherapy Advanced liver-associated cancers: metastatic colorectal cancer